How Social Distancing Helped Create a Sense of Community Among Some Patients with CLL

Video

Social distancing measures are keeping people apart, but that hasn't stopped some patients with CLL from finding a new sense of community.

While chronic lymphocytic leukemia (CLL) is the most common leukemia in adults, many patients in smaller communities may not meet another individual with the disease in their lifetime. But thanks to the new coronavirus 2019 (COVID-19) pandemic, support groups that previously met in person are now being held online and helping those in more rural areas connect to a larger community filled with people who understand what it’s like to live with this disease.

CURE recently spoke with Brian Koffman, the co-founder, executive vice president and chief medical officer of the CLL Society, about the importance of connecting with other patients and how moving support groups online has given a new sense of hope and community to individuals who may not have had access to that connection previously.

Transcription:

Because CLL is a relatively rare cancer compared to really well-established communities for breast cancer or even colon cancer and other cancers, there is tremendous solace for patients in seeing other patients.

When people meet people like me, a 15-year survivor — and not with a gentle form of CLL, but a very aggressive form of CLL – having met with me and seeing me, or with some of the other people in the group who are 17 years out or 20 years out, that says something to them that no doctor can ever say. They can look in the eye of another patient and say, “I was diagnosed 20 years ago, and I was scared to death, but now it’s 20 years later and I’ve seen my kids grow up and give me grandchildren.” It’s a tremendous message. And we don’t want that messaging to stop just because we can’t socially get together.

So, we think it’s even more important now because people are being isolated. (In these groups) there’s a lot of tips people can give about “where can I get a mask, what’s going on here”. I’ve attended a number of these groups and people have said “so-and-so will deliver groceries to you” because it’s a local group. The group in Seattle can give tips to somebody else in Seattle, saying, “have you tried so-and-so? They still have this supply or that supply,” and it’s been a tremendous resource for people beyond their normal family.

The other thing that’s been amazingly cool about this is that people in smaller communities, where they wouldn’t be able to put together a support group, have called in to some of the centers where it might be 100 miles away and they were going to drive in, now they’re right there in the same virtual room with everybody else. So, people from the smaller communities are able to join some of the bigger, established communities so they can realize they’re not alone. For some people, these virtual groups are the first time they’ve ever seen another CLL patient, especially people in small, rural communities.

We think it’s critically important to keep this going, and that’s the feedback we’re getting from patients, that they’re extraordinarily grateful for it. A lot of them like it because they don’t have to drive in the traffic. I live in the Los Angeles area and it can be two hours to get to one of our meetings. People like that they can just get on their laptop and type, type, type and they’re in!

Related Videos
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Yuliya P.L Linhares, MD, an expert on CLL
Video 8 - "Acalabrutinib-Based Treatment Clinical Trial Updates"
Video 7 - "Overview of Efficacy and Safety Data for Current CLL Treatment Options"
Josie Montegaard, MSN, AGPCNP-BC, an expert on CLL
Yuliya P.L Linhares, MD, an expert on CLL
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL